SCHEMBL1344053

SCHEMBL1344053

COc1ccccc1Oc1cc(F)ccc1NC(=O)CC(=O)Nc1nc(C(N)S(C)(=O)=O)c(SC)s1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CSNK1D P48730 1/20 0.40
HSD17B10 Q99714 2/20 0.37
TSHR P16473 1/20 0.37
POLB P06746 2/20 0.37
TP53 P04637 1/20 0.37
RAB9A P51151 3/20 0.37
NPC1 O15118 2/20 0.37
MAPT P10636 2/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
RORC P51449 1/20 0.36
PI4KB Q9UBF8 2/20 0.36
GAA P10253 2/20 0.35
ALDH1A1 P00352 2/20 0.35
LMNA P02545 1/20 0.35
PAX8 Q06710 1/20 0.35
SCN10A Q9Y5Y9 1/20 0.34
PKM P14618 1/20 0.34
HTT P42858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1342447 0.92 MEN1 (0.38) CSNK1DHSD17B10POLBTP53RAB9A
SCHEMBL1343610 0.90 CSNK1D (0.41) CSNK1DHSD17B10TSHRTP53RAB9A
SCHEMBL1342236 0.89 KMT2A (0.38) CSNK1DHSD17B10RAB9ANPC1MAPT
SCHEMBL1342284 0.89 CSNK1D (0.41) CSNK1DHSD17B10TSHRRAB9ANPC1
SCHEMBL1343052 0.85 MEN1 (0.35) CSNK1DMAPTMEN1KMT2AALDH1A1
SCHEMBL1344054 0.84 CSNK1D (0.43) CSNK1DHSD17B10TSHRPOLBTP53
SCHEMBL1341770 0.81 CSNK1D (0.44) CSNK1DHSD17B10TSHRPOLBRAB9A
SCHEMBL1342961 0.81 MEN1 (0.39) CSNK1DHSD17B10TP53RAB9ANPC1
SCHEMBL1343384 0.81 GRM4 (0.36) CSNK1DPOLBRAB9ANPC1MAPT
SCHEMBL1342600 0.81 RORC (0.42) CSNK1DHSD17B10TSHRPOLBRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063081-B2 N-(2-Phenoxyphenyl)-N'-(thiazol-2-yl)urea; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase NOVO NORDISK A/S (DK) 2011-11-22 US disclosed
US-7897628-B2 {2-[3-(4-Methyl-2-[2-methypropoxy]phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase NOVO NORDISK A/S (DK) 2011-03-01 US disclosed
EP-1531815-A1 GLUCOKINASE ACTIVATORS NOVO NORDISK A/S (DK) 2005-05-25 EP disclosed
US-20040122235-A1 Aryl carbonyl derivatives as therapeutic agents VTV THERAPEUTICS LLC 2004-06-24 US disclosed
WO-2004002481-A1 ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS NOVO NORDISK A/S (DK) 2004-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122235-A1 Aryl carbonyl derivatives as therapeutic agents GCK, GCKR, PDK2 CSNK1D 1591/4885HSD17B10 611/4885TSHR 2745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.